000766 通化金马
已收盘 09-14 15:00:00
资讯
新帖
简况
通化金马:公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作
证券之星 · 09-11
通化金马:公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作
通化金马:公司正按计划推进新药商业化相关各项工作
证券之星 · 09-09
通化金马:公司正按计划推进新药商业化相关各项工作
通化金马:琥珀酸安维吖啶片正在开展商业化生产
证券之星 · 09-09
通化金马:琥珀酸安维吖啶片正在开展商业化生产
股市必读:通化金马(000766)9月8日董秘有最新回复
证券之星 · 09-09
股市必读:通化金马(000766)9月8日董秘有最新回复
通化金马:琥珀酸安维吖啶片注册分类为化学药品1类
证券之星 · 08-26
通化金马:琥珀酸安维吖啶片注册分类为化学药品1类
通化金马:公司已针对新药建立独立的销售布局
证券之星 · 08-26
通化金马:公司已针对新药建立独立的销售布局
股市必读:通化金马新发布《2026年半年度报告摘要》
证券之星 · 08-24
股市必读:通化金马新发布《2026年半年度报告摘要》
股市必读:通化金马中报 - 第二季度单季净利润同比下降138.78%
证券之星 · 08-21
股市必读:通化金马中报 - 第二季度单季净利润同比下降138.78%
通化金马(000766)披露2026年半年度报告及其摘要,8月20日股价上涨4.92%
证券之星 · 08-20
通化金马(000766)披露2026年半年度报告及其摘要,8月20日股价上涨4.92%
通化金马(000766.SZ)发布上半年业绩,归母净利润710.46万元,同比下降57.72%
智通财经网 · 08-20
通化金马(000766.SZ)发布上半年业绩,归母净利润710.46万元,同比下降57.72%
公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产
格隆汇 · 08-12
公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产
股市必读:通化金马新发布《关于全资子公司签署《并购意向协议》的公告》
证券之星 · 08-10
股市必读:通化金马新发布《关于全资子公司签署《并购意向协议》的公告》
通化金马(000766)披露全资子公司签署《并购意向协议》公告,8月6日股价下跌1.04%
证券之星 · 08-06
通化金马(000766)披露全资子公司签署《并购意向协议》公告,8月6日股价下跌1.04%
通化金马最新公告:全资子公司拟收购八加一药业控股权
证券之星 · 08-06
通化金马最新公告:全资子公司拟收购八加一药业控股权
股市必读:通化金马(000766)8月4日董秘有最新回复
证券之星 · 08-05
股市必读:通化金马(000766)8月4日董秘有最新回复
通化金马:琥珀酸安维吖啶片已开展商业化生产
证券之星 · 08-04
通化金马:琥珀酸安维吖啶片已开展商业化生产
公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产
格隆汇 · 07-27
公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产
通化金马:7月8日高管张玉富增持股份合计6.07万股
证券之星 · 07-09
通化金马:7月8日高管张玉富增持股份合计6.07万股
通化金马:公司拥有琥珀酸安维吖啶片完全自主知识产权
证券之星 · 07-09
通化金马:公司拥有琥珀酸安维吖啶片完全自主知识产权
通化金马:关于董事长兼总经理增持公司股份计划的公告
证券之星 · 07-08
通化金马:关于董事长兼总经理增持公司股份计划的公告
加载更多
公司概况
公司名称:
通化金马药业集团股份有限公司
所属行业:
医药制造业
上市日期:
1997-04-30
主营业务:
通化金马药业集团股份有限公司的主营业务是医药产品的研发、生产与销售。公司的主要产品是琥珀酸安维吖啶片、复方嗜酸乳杆菌片、风湿祛痛胶囊、清肝健脾颗粒、芩石利咽口服液、乳酸亚铁口服液。公司获得了高新技术企业,荣获“中华民族医药百强品牌企业”、2015年度最具资本力企业奖、2017创新中国十大发展潜力企业、“2022-2023年度中国医药制造业百强”、2023年度中国化药企业TOP100等称号。
发行价格:
7.23
{"stockData":{"symbol":"000766","market":"SZ","secType":"STK","nameCN":"通化金马","latestPrice":15.63,"timestamp":1789369416000,"preClose":16.05,"halted":0,"volume":11560957,"delay":0,"changeRate":-0.0262,"floatShares":966000000,"shares":966000000,"eps":0.0255,"marketStatus":"已收盘","change":-0.42,"latestTime":"09-14 15:00:00","open":16,"high":16.06,"low":15.47,"amount":182000000,"amplitude":0.0368,"askPrice":15.64,"askSize":517,"bidPrice":15.63,"bidSize":529,"shortable":0,"etf":0,"ttmEps":0.0255,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":16.05,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":17.66,"lowLimit":14.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":966494707,"isCdr":false,"pbRate":6.69,"roa":"--","peRate":612.941176,"roe":"0.31%","epsLYR":0.04,"committee":-0.213863,"marketValue":15106000000,"turnoverRate":0.012,"status":1,"floatMarketCap":15093000000},"requestUrl":"/m/hq/s/000766","defaultTab":"news","newsList":[{"id":"2666484915","title":"通化金马:公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2666484915","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666484915?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:51","pubTimestamp":1789098666,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)09月10日在投资者关系平台上答复投资者关心的问题。投资者提问:新药价格何时公布?通化金马回复:您好,公司琥珀酸安维吖啶片已正式开展创新药首发价格挂网工作,首发价格定价以各省价格平台公示数据为准。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100024958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK0060","BK1161","BK0239","BK0077","BK1574","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666715533","title":"通化金马:公司正按计划推进新药商业化相关各项工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2666715533","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666715533?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:53","pubTimestamp":1788958388,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问:新药上市为何没人和营销宣传,药效好不用打广告?通化金马回复:您好,公司正按计划推进新药商业化相关各项工作,药品推广需遵守相关监管规定,后续进展请以公司公告为准,感谢关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900037341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","BK0239","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553374","title":"通化金马:琥珀酸安维吖啶片正在开展商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553374","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666553374?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:53","pubTimestamp":1788958388,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问:什么时候能买到新药通化金马回复:您好,公司琥珀酸安维吖啶片正在开展商业化生产并且推进首发价格挂网工作,当前新药的销售渠道协调和发货工作正在有序推进。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900037340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","BK0239","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374130","title":"股市必读:通化金马(000766)9月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374130?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:51","pubTimestamp":1788886276,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘,通化金马报收于17.17元,上涨2.39%,换手率1.63%,成交量15.78万手,成交额2.71亿元。董秘最新回复投资者: 吗利福肽什么时候可以完成二期临床董秘: 您好,有关本公司的重大信息,均会在指定信息披露媒体发布,请投资者关注公司公告。当日关注点交易信息汇总:9月8日主力资金净流入2757.92万元,占总成交额10.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662958047","title":"通化金马:琥珀酸安维吖啶片注册分类为化学药品1类","url":"https://stock-news.laohu8.com/highlight/detail?id=2662958047","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662958047?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:48","pubTimestamp":1787730494,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问:公司新药属于BIC并不是FIC吧,不能算创新药,还是老思路,不能逆转病情。通化金马回复:您好,根据《药品注册证书》,琥珀酸安维吖啶片注册分类为化学药品1类。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600031605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000766","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795803","title":"通化金马:公司已针对新药建立独立的销售布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662795803?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:48","pubTimestamp":1787730493,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问:新药建立独立的销售布局效率低,成员有经验,还是有什么销售计划,核爆级的?通化金马回复:您好,公司已针对新药建立独立的销售布局。如有涉及公司应披露的重大事项,公司将会严格按照相关法律法规的规定履行信息披露义务,请投资者关注公司公告。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600031604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000766","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661245381","title":"股市必读:通化金马新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661245381","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661245381?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:57","pubTimestamp":1787507829,"startTime":"0","endTime":"0","summary":"公司公告汇总:2026年半年度报告摘要显示,营业收入同比下降14.28%,归母净利润同比下降57.72%;公司决定不派发现金红利、不送红股、不以公积金转增股本。公司公告汇总:截至2026年半年度末,上市公司与子公司等关联方非经营性资金往来余额合计295,479,924.60元,无控股股东及实际控制人非经营性资金占用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0077","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661236034","title":"股市必读:通化金马中报 - 第二季度单季净利润同比下降138.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661236034","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661236034?lang=zh_cn&edition=full","pubTime":"2026-08-21 00:58","pubTimestamp":1787245088,"startTime":"0","endTime":"0","summary":"业绩披露要点:2026年第二季度单季度归母净利润为-202.47万元,同比下降138.78%。公司公告汇总:公司因执行财政部《企业会计准则解释第19号》《第20号》,自2026年1月1日起变更会计政策,无需提交董事会或股东会审议。其中第二季度单季度主营收入2.57亿元,同比下降26.7%;单季度归母净利润-202.47万元,同比下降138.78%;单季度扣非净利润-227.19万元,同比下降152.09%;负债率50.75%,投资收益55.49万元,财务费用4194.75万元,毛利率75.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100000911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400268","title":"通化金马(000766)披露2026年半年度报告及其摘要,8月20日股价上涨4.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400268","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400268?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:31","pubTimestamp":1787218317,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘,通化金马报收于16.86元,较前一交易日上涨4.92%,最新总市值为162.95亿元。该股当日开盘16.38元,最高17.3元,最低16.04元,成交额达5.31亿元,换手率为3.28%。近日,通化金马药业集团股份有限公司召开第十二届董事会第二次会议,审议通过公司2026年半年度报告及其摘要。会议通知于2026年8月10日以微信、电子邮件形式发出,会议由董事长张玉富主持,9名董事全部出席。公司2026年半年度报告及其摘要同日披露于巨潮资讯网。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","000766","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402396","title":"通化金马(000766.SZ)发布上半年业绩,归母净利润710.46万元,同比下降57.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402396","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402396?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:17","pubTimestamp":1787213874,"startTime":"0","endTime":"0","summary":"智通财经APP讯,通化金马 发布2026年半年度报告,报告期内,公司实现营业收入5.57亿元,同比下降14.28%。实现归属于上市公司股东的净利润710.46万元,同比下降57.72%。基本每股收益0.0074元。上半年,面对医药行业政策深化与市场环境变化,公司在董事会的正确领导和全体员工的不懈努力下,以创新驱动战略为引领,加快重点产品研发及产业化进程,稳步推进精益管理,持续优化营销体系和渠道布局,努力保持经营和业绩平稳发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"通化金马(000766.SZ)发布上半年业绩,归母净利润710.46万元,同比下降57.72%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658770922","title":"公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2658770922","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658770922?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:53","pubTimestamp":1786521185,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","BK0239","000766","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658670432","title":"股市必读:通化金马新发布《关于全资子公司签署《并购意向协议》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658670432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658670432?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:24","pubTimestamp":1786296252,"startTime":"0","endTime":"0","summary":"公司公告汇总:全资子公司桂林金马创新投资有限公司于8月6日与八加一药业签署《并购意向协议》,拟意向收购其控股权,交易尚处框架阶段,不构成重大资产重组,存在不确定性。公司公告汇总关于全资子公司签署《并购意向协议》的公告通化金马药业集团股份有限公司全资子公司桂林金马创新投资有限公司于2026年8月6日与八加一药业股份有限公司签署《并购意向协议》,意向收购八加一控股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","000766","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657630437","title":"通化金马(000766)披露全资子公司签署《并购意向协议》公告,8月6日股价下跌1.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657630437","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657630437?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:22","pubTimestamp":1786026140,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,通化金马报收于17.09元,较前一交易日下跌1.04%,最新总市值为165.17亿元。该股当日开盘17.28元,最高17.38元,最低16.92元,成交额达2.62亿元,换手率为1.58%。近日,通化金马药业集团股份有限公司披露公告,其全资子公司桂林金马创新投资有限公司于2026年8月6日与八加一药业股份有限公司签署《并购意向协议》,意向收购八加一控股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680688","title":"通化金马最新公告:全资子公司拟收购八加一药业控股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680688","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657680688?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:49","pubTimestamp":1786013377,"startTime":"0","endTime":"0","summary":"通化金马(000766.SZ)公告称,公司全资子公司桂林金马创新投资有限公司与八加一药业股份有限公司签署《并购意向协议》,拟收购其控股权。八加一获得药品研发专利23项,拥有2个1类化药新药品种的临床批件和1个1类中药新药品种的临床批件。本次交易为框架性协议,后续需经尽职调查和正式协议确定,存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600033366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000766","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565692","title":"股市必读:通化金马(000766)8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565692?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:45","pubTimestamp":1785869112,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,通化金马报收于17.71元,上涨1.84%,换手率1.77%,成交量17.14万手,成交额3.03亿元。董秘最新回复投资者: 互联网药房销售也希望公司一起打通,又快又有效!当日关注点交易信息汇总:8月4日主力资金净流入164.23万元,占总成交额0.54%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0077","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958168","title":"通化金马:琥珀酸安维吖啶片已开展商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958168","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656958168?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:48","pubTimestamp":1785815283,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马08月03日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,想咨询公司新药琥珀酸安维吖啶片(耄安通)相关产能问题:1、生产线满负荷状态下,每日最大设计产能为多少万片?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400016771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654709772","title":"公司问答丨通化金马:公司琥珀酸安维吖啶片已正式开展商业化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2654709772","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654709772?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:24","pubTimestamp":1785137051,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["000766","BK0239","BK0077","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650871922","title":"通化金马:7月8日高管张玉富增持股份合计6.07万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650871922","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650871922?lang=zh_cn&edition=full","pubTime":"2026-07-09 21:01","pubTimestamp":1783602068,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月9日市场公开信息、上市公司公告及交易所披露数据整理,通化金马(000766)最新董监高及相关人员股份变动情况:2026年7月8日公司高管,董事张玉富共增持公司股份6.07万股,占公司总股本为0.0063%。变动期间公司股价下跌7.89%,7月8日当日收盘报15.76元。通化金马近半年内的董监高及核心技术人员增减持详情如下:通化金马的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出1.68亿,融资余额减少;融券净流入4.69万,融券余额增加。该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、通化金马公告,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900040850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0077","000766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944061","title":"通化金马:公司拥有琥珀酸安维吖啶片完全自主知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650944061?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:48","pubTimestamp":1783583285,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马07月08日在投资者关系平台上答复投资者关心的问题。谢谢通化金马回复:您好,公司拥有琥珀酸安维吖啶片完全自主知识产权。公司已按有关要求推进琥珀酸安维吖啶片的2026年医保目录申报工作。详见公告编号为2024-25的《关于国家1类化学药琥珀八氢氨吖啶片相关专利保护情况的自愿性披露公告》、公告编号为2026-30的《关于获得琥珀酸安维吖啶片药品注册证书的公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900024551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","000766","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952299","title":"通化金马:关于董事长兼总经理增持公司股份计划的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649952299?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:51","pubTimestamp":1783482668,"startTime":"0","endTime":"0","summary":"证券之星消息,通化金马(000766)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,牧原在股价低迷时董高监等公司高管集体大额增持公司股票,以示信心。公司在董事长提出增持计划后,公司董高监会否参与回购,以示对公司信心和支持?通化金马回复:您好,我公司已发布公告编号为2026-31的《关于董事长兼总经理增持公司股份计划的公告》,张玉富先生计划增持公司股份。感谢关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800019563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789381264698,"stockEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0614},{"period":"3month","weight":-0.3654},{"period":"6month","weight":-0.2368},{"period":"1year","weight":-0.4038},{"period":"ytd","weight":-0.4162}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化金马药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"44735人(较上一季度增加4.02%)","perCapita":"21585股","listingDate":"1997-04-30","address":"吉林省通化市二道江区金马路999号","registeredCapital":"96649万元","survey":" 通化金马药业集团股份有限公司的主营业务是医药产品的研发、生产与销售。公司的主要产品是琥珀酸安维吖啶片、复方嗜酸乳杆菌片、风湿祛痛胶囊、清肝健脾颗粒、芩石利咽口服液、乳酸亚铁口服液。公司获得了高新技术企业,荣获“中华民族医药百强品牌企业”、2015年度最具资本力企业奖、2017创新中国十大发展潜力企业、“2022-2023年度中国医药制造业百强”、2023年度中国化药企业TOP100等称号。","listedPrice":7.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化金马,000766,通化金马股票,通化金马股票老虎,通化金马股票老虎国际,通化金马行情,通化金马股票行情,通化金马股价,通化金马股市,通化金马股票价格,通化金马股票交易,通化金马股票购买,通化金马股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}